Loading...
Market
Which EU country will first approve Wainzua by Q1 2025?
2
Resolution / Starting Odds
Germany • 25%
France • 25%
Italy • 25%
Spain • 25%
Official announcements from national health authorities or press releases from Ionis Pharmaceuticals or AstraZeneca
Story
CHMP Recommends Approval of Ionis and AstraZeneca's Wainzua for Rare Polyneuropathy
Oct 21, 2024, 06:10 AM
The Committee for Medicinal Products for Human Use (CHMP) in the EU has recommended the approval of Wainzua (eplontersen), a treatment developed by Ionis Pharmaceuticals and AstraZeneca, for adult patients with stage 1 or stage 2 polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. This recommendation marks a significant step forward for patients suffering from this rare condition.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
United States • 25%
Canada • 25%
Germany • 25%
Other • 25%
European Union • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
Germany • 25%
France • 25%
Spain • 25%
Other • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
Other • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
USA • 25%
UK • 25%
Germany • 25%
Other • 25%